BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene solid tumor pipeline and clinical trials.
Presentation from WCGI 2022 of the intermin analysis of the global double-blind Phase 3 RATIONALE-306 study evaluating first-line tislelizumab plus chemotherapy vs placebo plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Tislelizumab (BGB-A317) is an investigational humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.
